このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

ZKARE®ゲルおよびその付属品ZKAPI®の慢性潰瘍治療における有効性と安全性:前向き、無作為化、対照臨床試験。

2026年11月2日 更新者:i+Med S.Coop.

慢性潰瘍治療におけるZKARE®ゲルおよびその付属品ZKAPI®の有効性と安全性:前向き無作為化比較臨床試験

This prospective, randomized, single-blind, controlled clinical investigation evaluates the efficacy and safety of ZKARE®, a topical polymeric gel dressing, and its accessory applicator ZKAPI®, for the treatment of chronic, hard-to-heal ulcers. The study includes 134 ulcers of different etiologies-pressure ulcers, neuropathic diabetic foot ulcers, and venous leg ulcers-meeting predefined selection criteria. Participants are randomized to receive either ZKARE® in addition to standard wound care or standard care alone.

The primary efficacy endpoint is the change in wound condition assessed through the RESVECH 2.0 scale, recorded at baseline and throughout treatment and follow-up visits. The primary safety endpoint is the incidence of serious adverse events (SAEs). Secondary outcomes include percentage and rate of wound closure, total closure rate, estimated time to full closure, quality-of-life measures (DLQI), patient satisfaction, investigator global assessment, cost-effectiveness, and product usability. The study aims to generate evidence on the performance, safety, and clinical usefulness of ZKARE® for chronic wound management.

調査の概要

状態

募集

条件

介入・治療

詳細な説明

Chronic ulcers such as pressure ulcers, neuropathic diabetic foot ulcers and venous leg ulcers frequently fail to follow normal healing phases and require comprehensive management. Many existing dressings act through a single mechanism and are limited in effectiveness for complex or exudative wounds. ZKARE® is a sterile, biocompatible polymeric gel intended for topical use that provides a moist microenvironment, absorbs excess exudate and contributes to bacterial control. The product is applied using ZKAPI®, a sterile Luer-Lock applicator designed to improve precision and ease of administration.

This prospective, randomized, single-blind, controlled clinical investigation compares ZKARE® plus standard care with standard care alone in 134 chronic ulcers of different etiologies. Patients may contribute more than one ulcer if lesions are independent. After informed consent, ulcers are randomized, and treatment sessions follow routine clinical practice, with ZKARE® added only in the investigational arm. Blinding is maintained by preventing direct visualization of the wound and through iso-appearance of materials. Follow-up visits occur at approximately 2, 4, 8 and 12 weeks.

The primary efficacy endpoint is the change in RESVECH 2.0 score, recorded at baseline, each treatment session and all follow-up visits; a ≥2-point improvement at Week 4 is considered clinically relevant. The primary safety endpoint is the incidence of serious adverse events. Secondary outcomes include percentage and rate of wound closure, total closure rate, estimated time to full closure, DLQI, patient satisfaction, investigator global assessment, usability and cost-effectiveness, as well as non-serious adverse events.

Group comparisons use appropriate statistical tests for categorical and continuous variables, repeated-measures analyses and ANCOVA where applicable, under an intention-to-treat approach. The sample size of 134 ulcers gives 80% power to detect expected differences in RESVECH 2.0 change. The study aims to evaluate the clinical performance and safety of ZKARE® and ZKAPI® in the treatment of chronic hard-to-heal ulcers

研究の種類

介入

入学 (推定)

134

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Adult patients (≥18 years).
  • Presence of at least one chronic hard-to-heal ulcer, including any of the following etiologies: Grade II, III or IV pressure ulcers; neuropathic diabetic foot ulcers (grade I, II or III), Wagner Grade I-III or Texas 0, I, II, III / Stage B; class C6/C6r venous leg ulcers measured with CEAP scale ; neuro-ischaemic ulcers with adequate distal perfusion (ABI/ITB ≥ 0.7-0.89; mild PAD); mixed-etiology venous ulcers and any chronic lower-limb lesion with palpable distal pulses.
  • Ulcer size between 1 cm² and 100 cm².
  • Ability and willingness to comply with all study visits and procedures according to the clinical protocol.
  • Ability to understand and sign the informed consent, obtained before performing any protocol-specific procedures.

Exclusion Criteria:

  • Ulcers of etiologies not listed in the inclusion criteria.
  • Ischaemic, neoplastic or atypical ulcers.
  • Severe comorbidities judged to compromise safety or study compliance, including: severe malnutrition, palliative/terminal status, severe anemia, decompensated heart failure, chronic kidney disease stage III/IV or in dialysis.
  • Ulcers with moderate-severe or severe infection per PEDIS-IDSA infection grading scale.
  • Known allergy or sensitivity to any component of the investigational product.
  • Any condition that, in the investigator's opinion, may compromise patient safety or adherence to the protocol.
  • Pregnancy or planned breastfeeding.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:ZKARE®

Participants assigned to this arm receive standard wound care plus topical application of the investigational gel ZKARE®, applied using the ZKAPI® applicator during each wound-care session.

ZKARE® is applied topically after routine wound cleansing and debridement. Using the sterile ZKAPI® applicator, the gel is distributed to fully cover the wound bed, including irregular or cavitated areas. The treated wound is then covered with the appropriate secondary dressing following standard clinical practice. The application is repeated at each treatment session until complete closure or the end of the 12-week follow-up period. All sessions include RESVECH 2.0 scoring, standardized photographs, and safety assessments

アクティブコンパレータ:Standard Wound Care

Participants assigned to this arm receive standard wound management according to routine clinical practice, without the use of the investigational product.

Standard care includes wound cleansing, debridement when required, and selection of secondary dressings according to wound characteristics such as exudate level, infection status, depth, and perilesional skin condition. No investigational gel is applied. At each treatment visit and follow-up time point, standardized wound photographs, RESVECH 2.0 scoring, closure metrics, and safety assessments are recorded according to the same schedule as the investigational arm.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
RESVECH Scale 2.0
時間枠:12 weeks or wound healing

Change in the RESVECH 2.0 wound assessment scale, which evaluates wound size, depth, granulation tissue quality, exudate amount/type, clinical signs of infection/inflammation, and perilesional skin condition.

Measured at baseline and at each treatment and follow-up visit until complete closure or at week 12. A ≥2-point improvement at week 4 is considered clinically relevant.

12 weeks or wound healing
Incidence of Serious Adverse Events (SAEs)
時間枠:12 weeks

Incidence, frequency, and nature of serious adverse events during the study.

12 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Wound Closure Rate (mm²/day)
時間枠:12 weeks

Rate of epithelialization based on the area healed divided by the time since treatment initiation.

Assessed at each treatment and follow-up visit.

12 weeks
Percentage of Wound Closure (%)
時間枠:12 weeks

Percentage reduction of the initial wound area at each assessment. A ≥30% reduction by week 4 is considered clinically relevant.

Kaplan-Meier curves may be used to evaluate closure thresholds (≥30%-90%).

12 weeks
Total Wound Closure (%)
時間枠:12 weeks

Percentage of wounds achieving complete epithelialization.

12 weeks
Estimated Time to Full Closure (days)
時間枠:12 weeks

For wounds not completely healed by week 12, linear regression based on closure rate is used to estimate time to complete healing.

12 weeks
Cost-Effectiveness Analysis (Healthcare Resources Used)
時間枠:12 weeks

Quantification of materials, products, consumables, and healthcare professional time in each treatment session.

Reported as €/patient.

12 weeks
Dermatology Life Quality Index (DLQI) Score
時間枠:12 weeks

Change in DLQI score (0-30), with higher scores indicating worse dermatology-related quality of life.

12 weeks
Patient Satisfaction (Likert Scale)
時間枠:12 weeks

Patient satisfaction rated at study end (Very dissatisfied, dissatisfied, neutral, satisfied and very satisfied).

Outcome to be reported as the percentage of "Satisfied" + "Very satisfied" answers.

12 weeks
Investigator Global Assessment (IGA)
時間枠:12 weeks

Clinical impression of overall wound evolution (Worsening / No improvement / Mild improvement / Significant improvement).

Outcome to be reported as the percentage of mild or significant improvement achievement.

12 weeks
Incidence of Non-Serious Adverse Events (AEs)
時間枠:12 weeks

Recording of the incidence and nature of all non-serious adverse events.

12 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年11月14日

一次修了 (推定)

2027年3月1日

研究の完了 (推定)

2027年8月1日

試験登録日

最初に提出

2026年2月5日

QC基準を満たした最初の提出物

2026年2月5日

最初の投稿 (実際)

2026年2月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月4日

QC基準を満たした最後の更新が送信されました

2026年11月2日

最終確認日

2026年2月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • ZKARE-PIC01-2025

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。